About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results

CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed several encouraging results that suggest real potential for patients living with this rare disease.

While the trial (conducted in 268 patients in the U.S., Europe, Japan, and Brazil) did not achieve the primary goal of reducing oral corticosteroid use compared to placebo, findings for other study outcome measures suggest that efzofitimod helped more patients completely withdraw from steroids and improved measures of quality of life alongside stable lung function, with a favorable safety profile.

“We greatly appreciate the patients with sarcoidosis and their families who generously participated in the EFZO-FIT™ study. Their commitment made it possible to further essential research aimed at improving understanding and treatment of sarcoidosis,” said Mary McGowan, President and CEO of FSR. “FSR also thanks the investigators, clinical teams, and research partners who supported this study. FSR remains committed to advancing innovative research and ensuring patient perspectives are central to future trial design and drug development efforts. We look forward to learning more as aTyr takes deeper dives into the robust trial data that will allow us to learn more about sarcoidosis.”

FSR encourages all stakeholders—patients, researchers, drug development companies, and regulators—to build upon the knowledge generated from this clinical trial as the largest interventional study completed in sarcoidosis thus far. Continued investment in patient-focused clinical trial design, natural history studies, and the inclusion of patient perspectives in defining outcome measures is essential to advance new, effective therapies.

As aTyr plans to consult with the FDA regarding future options for efzofitimod, FSR looks forward to continuing to support this conversation and to ensure the inclusion of the patient perspective when considering next steps. FSR is grateful to aTyr Pharma for their commitment to prioritizing outcomes important to the patient community, as was strongly emphasized at FSR's Externally-Led Patient-Focused Drug Development meeting on sarcoidosis with the FDA in October 2024.

"There remains an urgent need for a safe and effective treatment option to address the unmet needs of this underserved population," said Sanjay Shukla, aTyr CEO. “We are encouraged by the potential of efzofitimod to improve the lives of those living with sarcoidosis, and we are incredibly grateful to the patients, investigators, and patient advocacy organizations... who all contributed to this important study."

FSR looks forward to exploring further into the EFZO-FIT™ trial data and collaborating with researchers, clinicians, and individuals living with sarcoidosis to learn as much as possible from this important research. This study provides valuable insights into the management of pulmonary sarcoidosis, underscoring the potential for therapies that meaningfully lessen steroid burden while preserving patient quality of life.

About Sarcoidosis
Sarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States.

About the Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: www.stopsarcoidosis.org.

About aTyr Pharma
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Media Contact:
Cathi Davis, Director of Communications and Marketing
Foundation for Sarcoidosis Research
312-341-0500
cathi@stopsarcoidosis.org


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.